Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

Source: Press Release IGM Biosciences: Dizzying Number Of Pivots IGM to slash 73% of workforce, halt two drug programs Seeking Alpha’s Quant Rating on IGM Biosciences Historical earnings data ...

Green Alpha Advisors LLC’s holdings in Pacific Biosciences of California were worth $187,000 as of its most recent SEC filing. Other institutional investors also recently added to or reduced ...